PMID- 25462893
OWN - NLM
STAT- MEDLINE
DCOM- 20150821
LR  - 20220310
IS  - 1873-3360 (Electronic)
IS  - 0306-4530 (Linking)
VI  - 51
DP  - 2015 Jan
TI  - The interplay between BDNF and oxidative stress in chronic schizophrenia.
PG  - 201-8
LID - S0306-4530(14)00377-1 [pii]
LID - 10.1016/j.psyneuen.2014.09.029 [doi]
AB  - Neurodegenerative processes may be involved in the pathogenesis of schizophrenia. 
      Brain-derived neurotrophic factor (BDNF), the most widely distributed 
      neurotrophin and oxidative stress (OS) may be critical for several pathological 
      manifestations of neurodegenerative disorders. Accumulating evidence suggests 
      that both BDNF and OS may be involved in the pathophysiology of schizophrenia. 
      However, the possible interaction between BDNF and OS has been 
      under-investigated. Serum BDNF, plasma malondialdehyde (MDA) levels and 
      superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and catalase (CAT) 
      activities were analyzed using established procedures in 164 chronic medicated 
      schizophrenia and 50 healthy controls. Schizophrenic symptoms were assessed by 
      the Positive and Negative Syndrome Scale (PANSS) with cognitive and depressive 
      factors derived from the five factor model of the PANSS. Compared to the control 
      group, the patients exhibited a significant decrease in BDNF levels, in the 
      activities of SOD and GSH-Px but a significant increase in MDA levels. In 
      patients, but not in controls, we observed a significant negative correlation 
      between BDNF and SOD. Furthermore, the interaction between BDNF and CAT was 
      associated with the PANSS cognitive factor, and the interaction between BDNF and 
      GSH-Px with the PANSS depressive factor. Both decreased BDNF levels and OS may be 
      implicated in the pathophysiology of chronic schizophrenia. Their inverse 
      association only in the schizophrenia group may reflect a pathological mechanism 
      involving an interaction of oxidative damage and neurotrophin dysfunction. 
      Moreover, OS may interact with the BDNF system to influence the clinical symptoms 
      and cognitive impairment in schizophrenia, which is line with the 
      neurodevelopmental hypothesis of schizophrenia.
CI  - Copyright (c) 2014 Elsevier Ltd. All rights reserved.
FAU - Zhang, Xiang Yang
AU  - Zhang XY
AD  - Beijing HuiLongGuan Hospital, Peking University, Beijing, China; Department of 
      Psychiatry and Behavioral Sciences, Harris County Psychiatric Center, The 
      University of Texas Health Science Center at Houston, Houston, TX, USA. 
      Electronic address: xiang.y.zhang@uth.tmc.edu.
FAU - Chen, Da-Chun
AU  - Chen DC
AD  - Beijing HuiLongGuan Hospital, Peking University, Beijing, China.
FAU - Tan, Yun-Long
AU  - Tan YL
AD  - Beijing HuiLongGuan Hospital, Peking University, Beijing, China.
FAU - Tan, Shu-Ping
AU  - Tan SP
AD  - Beijing HuiLongGuan Hospital, Peking University, Beijing, China.
FAU - Wang, Zhi-Ren
AU  - Wang ZR
AD  - Beijing HuiLongGuan Hospital, Peking University, Beijing, China.
FAU - Yang, Fu-De
AU  - Yang FD
AD  - Beijing HuiLongGuan Hospital, Peking University, Beijing, China.
FAU - Okusaga, Olaoluwa O
AU  - Okusaga OO
AD  - Department of Psychiatry and Behavioral Sciences, Harris County Psychiatric 
      Center, The University of Texas Health Science Center at Houston, Houston, TX, 
      USA.
FAU - Zunta-Soares, Giovana B
AU  - Zunta-Soares GB
AD  - Department of Psychiatry and Behavioral Sciences, Harris County Psychiatric 
      Center, The University of Texas Health Science Center at Houston, Houston, TX, 
      USA.
FAU - Soares, Jair C
AU  - Soares JC
AD  - Department of Psychiatry and Behavioral Sciences, Harris County Psychiatric 
      Center, The University of Texas Health Science Center at Houston, Houston, TX, 
      USA. Electronic address: jair.c.soares@uth.tmc.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141007
PL  - England
TA  - Psychoneuroendocrinology
JT  - Psychoneuroendocrinology
JID - 7612148
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - EC 1.11.1.6 (Catalase)
RN  - EC 1.11.1.9 (Glutathione Peroxidase)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
SB  - IM
CIN - Psychoneuroendocrinology. 2015 May;55:144-5. PMID: 25765755
MH  - Adult
MH  - Aged
MH  - Antipsychotic Agents/therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Catalase/blood
MH  - Female
MH  - Glutathione Peroxidase/blood
MH  - Humans
MH  - Male
MH  - Malondialdehyde/blood
MH  - Middle Aged
MH  - Oxidative Stress/*physiology
MH  - Psychiatric Status Rating Scales
MH  - Schizophrenia/*blood/drug therapy
MH  - Schizophrenic Psychology
MH  - Superoxide Dismutase/blood
OTO - NOTNLM
OT  - Brain-derived neurotrophic factor
OT  - Cognition
OT  - Interaction
OT  - Oxidative stress
OT  - Psychopathology
OT  - Schizophrenia
EDAT- 2014/12/03 06:00
MHDA- 2015/08/22 06:00
CRDT- 2014/12/03 06:00
PHST- 2014/07/10 00:00 [received]
PHST- 2014/09/06 00:00 [revised]
PHST- 2014/09/29 00:00 [accepted]
PHST- 2014/12/03 06:00 [entrez]
PHST- 2014/12/03 06:00 [pubmed]
PHST- 2015/08/22 06:00 [medline]
AID - S0306-4530(14)00377-1 [pii]
AID - 10.1016/j.psyneuen.2014.09.029 [doi]
PST - ppublish
SO  - Psychoneuroendocrinology. 2015 Jan;51:201-8. doi: 10.1016/j.psyneuen.2014.09.029. 
      Epub 2014 Oct 7.